Valuation: Swedish Orphan Biovitrum AB

Capitalization 13TCr 1.42TCr 1.23TCr 1.11TCr 1.07TCr 1.95TCr 1,30600Cr 2.04TCr 5.27TCr 63TCr 5.34TCr 5.22TCr 2,24400Cr P/E ratio 2025
243x
P/E ratio 2026 * 23.3x
Enterprise value 14TCr 1.54TCr 1.33TCr 1.2TCr 1.16TCr 2.11TCr 1,41200Cr 2.2TCr 5.69TCr 68TCr 5.77TCr 5.65TCr 2,42600Cr EV / Sales 2025
4.06x
EV / Sales 2026 * 4.64x
Free-Float
51.66%
Yield 2025 *
-
Yield 2026 * -

Last Transcript: Swedish Orphan Biovitrum AB

1 day-1.29%
1 week-4.56%
Current month-3.59%
1 month-1.50%
3 months+11.27%
6 months+38.02%
Current year+14.54%
1 week 376.8
Extreme 376.8
395
1 month 376.8
Extreme 376.8
432.8
Current year 322
Extreme 322
432.8
1 year 241.8
Extreme 241.8
432.8
3 years 197.9
Extreme 197.9
432.8
5 years 127.1
Extreme 127.1
432.8
10 years 89.5
Extreme 89.5
432.8
Manager TitleAgeSince
Chief Executive Officer 61 22/05/2017
Director of Finance/CFO 59 20/07/2018
Chief Tech/Sci/R&D Officer 55 -
Director TitleAgeSince
Director/Board Member 57 01/01/2020
Director/Board Member 70 01/01/2021
Director/Board Member - -
Change 5d. change 1-year change 3-years change Capi.($)
-1.29%-4.56%+22.73%+57.33% 1.46TCr
-2.87%-0.76%+11.32%-1.84% 8.08TCr
-1.98%+3.82%+31.82%+222.78% 5.82TCr
-0.59%-0.80%-44.43%-50.57% 4.86TCr
+8.64%+64.70%+64.70%+64.70% 4.8TCr
-0.98%+0.03%+30.82%-30.41% 2.79TCr
-6.87%+4.10%+52.88%-62.41% 2.28TCr
-1.55%-2.76%+39.42%+25.49% 1.97TCr
+4.72%-3.64%+103.22%+93.17% 1.72TCr
-0.56%-2.13%+89.22%+508.74% 1.29TCr
Average -0.36%-2.28%+40.17%+82.70% 3.51TCr
Weighted average by Cap. -0.36%-1.43%+27.99%+59.05%

Financials

2025 2026 *
Net sales 2.84TCr 306.83Cr 265.34Cr 240.28Cr 230.68Cr 420.74Cr 28TCr 439.28Cr 1.14TCr 14TCr 1.15TCr 1.13TCr 48TCr 3.1TCr 334.28Cr 289.08Cr 261.78Cr 251.32Cr 458.38Cr 31TCr 478.58Cr 1.24TCr 15TCr 1.25TCr 1.23TCr 53TCr
Net income 63Cr 6.83Cr 5.91Cr 5.35Cr 5.13Cr 9.37Cr 627.19Cr 9.78Cr 25Cr 300.5Cr 26Cr 25Cr 1.08TCr 574.94Cr 62Cr 54Cr 49Cr 47Cr 85Cr 5.7TCr 89Cr 229.74Cr 2.73TCr 232.91Cr 227.93Cr 9.79TCr
Net Debt 1.07TCr 115.27Cr 100Cr 90Cr 87Cr 158.06Cr 11TCr 165.03Cr 426.75Cr 5.07TCr 432.62Cr 423.38Cr 18TCr 1.18TCr 127.57Cr 110.32Cr 100Cr 96Cr 174.93Cr 12TCr 182.64Cr 472.29Cr 5.61TCr 478.79Cr 468.56Cr 20TCr
Logo Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (publ) is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.
Employees
1,888
Date Price Change Volume
05/26/05 381.20 kr -1.29% 3,19,160
04/26/04 386.20 kr +0.99% 3,19,083
03/26/03 382.40 kr -1.54% 3,77,984
02/26/02 388.40 kr -1.77% 3,25,579
27/26/27 395.40 kr -1.00% 7,68,630
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
381.20SEK
Average target price
423.60SEK
Spread / Average Target
+11.12%

Quarterly revenue - Rate of surprise